Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference
Ovid Therapeutics (NASDAQ:OVID), a biopharmaceutical company focused on developing small molecule medicines for brain conditions, announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The conference is scheduled for July 29-30, 2025.
Ovid Therapeutics (NASDAQ:OVID), un'azienda biofarmaceutica specializzata nello sviluppo di farmaci a piccola molecola per patologie cerebrali, ha annunciato la sua partecipazione al prossimo BTIG Virtual Biotechnology Conference. La conferenza si terrà il 29-30 luglio 2025.
Ovid Therapeutics (NASDAQ:OVID), una empresa biofarmacéutica centrada en el desarrollo de medicamentos de moléculas pequeñas para afecciones cerebrales, anunció su participación en la próxima Conferencia Virtual de Biotecnología BTIG. La conferencia está programada para el 29-30 de julio de 2025.
Ovid Therapeutics (NASDAQ:OVID)는 뇌 질환을 위한 소분자 약물 개발에 주력하는 생명공학 제약 회사로, 다가오는 BTIG 가상 바이오테크놀로지 컨퍼런스에 참여한다고 발표했습니다. 컨퍼런스는 2025년 7월 29-30일에 예정되어 있습니다.
Ovid Therapeutics (NASDAQ:OVID), une entreprise biopharmaceutique spécialisée dans le développement de médicaments à petites molécules pour les affections cérébrales, a annoncé sa participation à la prochaine Conférence virtuelle BTIG sur la biotechnologie. La conférence est prévue pour les 29 et 30 juillet 2025.
Ovid Therapeutics (NASDAQ:OVID), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von kleinen Molekülmedikamenten für Hirnerkrankungen spezialisiert hat, gab seine Teilnahme an der bevorstehenden BTIG Virtual Biotechnology Conference bekannt. Die Konferenz findet am 29. und 30. Juli 2025 statt.
- None.
- None.
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, announced today that the Company’s management will participate in the BTIG Virtual Biotechnology Conference being held on July 29-30, 2025.
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. For more information about these and other Ovid research programs, please visit www.ovidrx.com.
Investor Relations
Victoria Fort
202-361-0445
VFort@ovidrx.com
FAQ
When is Ovid Therapeutics (OVID) participating in the BTIG Virtual Biotechnology Conference?
What is Ovid Therapeutics' (OVID) main business focus?
Where can investors access Ovid Therapeutics' (OVID) BTIG conference presentation?
What type of conference is OVID participating in?
